LANOXIN (digoxin) is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves of
Digitalis lanata. The term "digitalis" is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence "glycosides").
Heart Failure: LANOXIN is indicated for the treatment of mild to moderate heart failure. LANOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, LANOXIN should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified.
Atrial Fibrillation: LANOXIN is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation.
Published Studies Related to Lanoxin Pediatric (Digoxin Pediatric)
The study of antiarrhythmic medications in infancy (SAMIS): a multicenter,
randomized controlled trial comparing the efficacy and safety of digoxin versus
propranolol for prophylaxis of supraventricular tachycardia in infants. 
CONCLUSIONS: There was no difference in SVT recurrence in infants treated with
Single daily dose of digoxin for maintenance therapy of infants and children with cardiac disease: is it reliable? [1994.09]
Between July 1990 and September 1991, 30 infants and children, most of whom had a congenital heart defect and who had been treated at least during the previous 20 days by two daily doses of digoxin and were in a stable clinical condition, were selected at random...
Intravenous amiodarone used alone or in combination with digoxin for life-threatening supraventricular tachyarrhythmia in neonates and small infants. [2010.02]
OBJECTIVES: The purpose of this study was to report the efficacy of intravenous amiodarone alone or in combination with digoxin in neonates and small infants with life-threatening supraventricular tachyarrhythmia (SVT)... CONCLUSIONS: Intravenous amiodarone alone or in combination with digoxin was found to be safe and effective in controlling refractory and life-threatening SVT in neonates and small infants.
Population pharmacokinetics of digoxin in Thai pediatric patients. [2009.10]
CONCLUSION: This simple final population model of Vd and CL can be used in clinical practice for estimating appropriate dosage regimen of loading dose and maintenance dose, respectively. Current weight, height, and presence of CHF should be taken into account when designing dosage regimen for individualized pediatric patients.
Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin. 
We report here the successful treatment of a 16-year-old female who ingested 20 tablets of digoxin each containing 0.25 mg (total dose ingested equivalent to 0.1 mg/kg), 32 tablets of warfarin each containing 5mg (equivalent to 3.2 mg/kg), and approximately 15 tablets of propafenone each containing 300 mg (equivalent to 90 mg/kg)...
Clinical Trials Related to Lanoxin Pediatric (Digoxin Pediatric)
Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care [Completed]
Dosing methods for digoxin, a drug used to treat heart failure, have not been updated in
decades despite evidence in recent years suggesting that blood levels of digoxin achieved
with traditional dosing practices may increase the risk of adverse events. We developed a
simple dosing tool that targets lower blood levels of digoxin that have been associated with
improved outcomes compared to higher blood levels. The aim of this study is to determine if
this simplified dosing tool is more effective than standard digoxin dosing practices at
achieving lower blood levels and also to determine if digoxin dosing may be further
optimized by incorporating patients' genetic information believed to influence the drug's
Drug Interaction Study of Isavuconazole and Digoxin [Completed]
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers. [Completed]
The purpose of this study is to determine how multiple doses of canagliflozin (JNJ-28431754)
affect the pharmacokinetics (ie, how the body affects the drug) of multiple doses of
digoxin. The safety and tolerability of canagliflozin will also be assessed in healthy
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects [Completed]
The purpose of this study is to evaluate the effect of steady state solifenacin and
mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will
also evaluate the safety and tolerability of the combined steady state administration of
solifenacin, mirabegron and digoxin.
A Trial of Digoxin Before Second-Trimester Abortion [Completed]